vs
C4 Therapeutics, Inc.（CCCC）与NexPoint Real Estate Finance, Inc.（NREF）财务数据对比。点击上方公司名可切换其他公司
NexPoint Real Estate Finance, Inc.的季度营收约是C4 Therapeutics, Inc.的1.0倍（$11.1M vs $11.0M），NexPoint Real Estate Finance, Inc.净利率更高（216.6% vs -186.0%，领先402.6%），C4 Therapeutics, Inc.同比增速更快（112.8% vs -48.8%）
C4 Therapeutics是一家临床阶段生物制药企业，专注于开发靶向蛋白降解疗法，用于治疗癌症及其他存在重大未满足医疗需求的严重疾病。公司依托自有专利TORPEDO平台设计小分子降解剂清除致病蛋白，目前拥有多条肿瘤领域研发管线，并与头部制药企业达成战略合作。
NexPoint Real Estate Finance, Inc.是一家总部位于美国的商业地产金融企业，主要为多户住宅、写字楼、工业及酒店物业提供结构化融资方案，运营并管理抵押贷款及其他地产相关投资组合，为利益相关方提供经风险调整的稳定回报。
CCCC vs NREF — 直观对比
营收规模更大
NREF
是对方的1.0倍
$11.0M
营收增速更快
CCCC
高出161.6%
-48.8%
净利率更高
NREF
高出402.6%
-186.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $11.0M | $11.1M |
| 净利润 | $-20.5M | $24.0M |
| 毛利率 | — | — |
| 营业利润率 | -210.1% | — |
| 净利率 | -186.0% | 216.6% |
| 营收同比 | 112.8% | -48.8% |
| 净利润同比 | 40.7% | 58.7% |
| 每股收益（稀释后） | $-0.09 | $0.47 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CCCCNREF
| Q4 25 | $11.0M | $11.1M | ||
| Q3 25 | $11.2M | $12.5M | ||
| Q2 25 | $6.5M | $12.1M | ||
| Q1 25 | $7.2M | $11.5M | ||
| Q4 24 | $5.2M | $21.7M | ||
| Q3 24 | $15.4M | $12.5M | ||
| Q2 24 | $12.0M | $6.7M | ||
| Q1 24 | $3.0M | $-12.8M |
净利润CCCCNREF
| Q4 25 | $-20.5M | $24.0M | ||
| Q3 25 | $-32.2M | $50.9M | ||
| Q2 25 | $-26.0M | $22.3M | ||
| Q1 25 | $-26.3M | $26.0M | ||
| Q4 24 | $-34.6M | $15.2M | ||
| Q3 24 | $-24.7M | $23.3M | ||
| Q2 24 | $-17.7M | $12.1M | ||
| Q1 24 | $-28.4M | $-14.6M |
营业利润率CCCCNREF
| Q4 25 | -210.1% | — | ||
| Q3 25 | -306.4% | — | ||
| Q2 25 | -441.0% | — | ||
| Q1 25 | -402.9% | — | ||
| Q4 24 | -728.4% | — | ||
| Q3 24 | -183.9% | — | ||
| Q2 24 | -178.6% | — | ||
| Q1 24 | -1060.2% | — |
净利率CCCCNREF
| Q4 25 | -186.0% | 216.6% | ||
| Q3 25 | -286.4% | 407.0% | ||
| Q2 25 | -402.6% | 184.5% | ||
| Q1 25 | -363.7% | 225.6% | ||
| Q4 24 | -667.8% | 69.9% | ||
| Q3 24 | -160.6% | 186.4% | ||
| Q2 24 | -147.6% | 179.7% | ||
| Q1 24 | -933.2% | 114.3% |
每股收益（稀释后）CCCCNREF
| Q4 25 | $-0.09 | $0.47 | ||
| Q3 25 | $-0.44 | $1.14 | ||
| Q2 25 | $-0.37 | $0.54 | ||
| Q1 25 | $-0.37 | $0.70 | ||
| Q4 24 | $-0.50 | $0.71 | ||
| Q3 24 | $-0.35 | $0.74 | ||
| Q2 24 | $-0.26 | $0.40 | ||
| Q1 24 | $-0.41 | $-0.83 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $74.6M | $31.1M |
| 总债务越低越好 | — | $771.2M |
| 股东权益账面价值 | $256.6M | $388.0M |
| 总资产 | $359.1M | $5.3B |
| 负债/权益比越低杠杆越低 | — | 1.99× |
8季度趋势，按日历期对齐
现金及短期投资CCCCNREF
| Q4 25 | $74.6M | $31.1M | ||
| Q3 25 | $58.8M | $17.9M | ||
| Q2 25 | $78.2M | $9.1M | ||
| Q1 25 | $51.3M | $19.2M | ||
| Q4 24 | $55.5M | $3.9M | ||
| Q3 24 | $59.6M | $34.7M | ||
| Q2 24 | $73.1M | $4.3M | ||
| Q1 24 | $89.7M | $13.5M |
总债务CCCCNREF
| Q4 25 | — | $771.2M | ||
| Q3 25 | — | $720.9M | ||
| Q2 25 | — | $815.6M | ||
| Q1 25 | — | $831.5M | ||
| Q4 24 | — | $799.3M | ||
| Q3 24 | — | $815.5M | ||
| Q2 24 | — | $861.0M | ||
| Q1 24 | — | $843.3M |
股东权益CCCCNREF
| Q4 25 | $256.6M | $388.0M | ||
| Q3 25 | $154.4M | $375.4M | ||
| Q2 25 | $174.1M | $348.2M | ||
| Q1 25 | $195.1M | $343.7M | ||
| Q4 24 | $216.0M | $336.5M | ||
| Q3 24 | $242.7M | $335.8M | ||
| Q2 24 | $247.1M | $327.5M | ||
| Q1 24 | $258.3M | $327.1M |
总资产CCCCNREF
| Q4 25 | $359.1M | $5.3B | ||
| Q3 25 | $265.5M | $5.3B | ||
| Q2 25 | $296.5M | $5.4B | ||
| Q1 25 | $319.5M | $5.4B | ||
| Q4 24 | $349.6M | $5.4B | ||
| Q3 24 | $376.1M | $5.7B | ||
| Q2 24 | $381.1M | $6.6B | ||
| Q1 24 | $398.4M | $7.1B |
负债/权益比CCCCNREF
| Q4 25 | — | 1.99× | ||
| Q3 25 | — | 1.92× | ||
| Q2 25 | — | 2.34× | ||
| Q1 25 | — | 2.42× | ||
| Q4 24 | — | 2.38× | ||
| Q3 24 | — | 2.43× | ||
| Q2 24 | — | 2.63× | ||
| Q1 24 | — | 2.58× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-22.1M | $-4.5M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | -0.19× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流CCCCNREF
| Q4 25 | $-22.1M | $-4.5M | ||
| Q3 25 | $-31.2M | $8.1M | ||
| Q2 25 | $-12.1M | $3.3M | ||
| Q1 25 | $-33.3M | $16.0M | ||
| Q4 24 | $-17.9M | $4.4M | ||
| Q3 24 | $-24.1M | $14.7M | ||
| Q2 24 | $-5.0M | $-7.5M | ||
| Q1 24 | $-18.1M | $17.7M |
自由现金流CCCCNREF
| Q4 25 | — | — | ||
| Q3 25 | $-31.6M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $-17.9M | — | ||
| Q3 24 | $-24.1M | — | ||
| Q2 24 | $-5.2M | — | ||
| Q1 24 | — | — |
自由现金流率CCCCNREF
| Q4 25 | — | — | ||
| Q3 25 | -281.5% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -346.5% | — | ||
| Q3 24 | -157.2% | — | ||
| Q2 24 | -43.1% | — | ||
| Q1 24 | — | — |
资本支出强度CCCCNREF
| Q4 25 | — | — | ||
| Q3 25 | 3.7% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.1% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 1.6% | — | ||
| Q1 24 | 0.0% | — |
现金转化率CCCCNREF
| Q4 25 | — | -0.19× | ||
| Q3 25 | — | 0.16× | ||
| Q2 25 | — | 0.15× | ||
| Q1 25 | — | 0.62× | ||
| Q4 24 | — | 0.29× | ||
| Q3 24 | — | 0.63× | ||
| Q2 24 | — | -0.62× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
